DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Chylomicronemia Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Familial Chylomicronemia Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Familial Chylomicronemia Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Familial Chylomicronemia Syndrome: An Overview
Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by an increase in the triglycerides (TGs) level due to a reduction in the LPL, which is an enzyme that helps to break down chylomicrons (CMs) in the body. The reduction in the LPL leads to the buildup of CMs which are rich in triglycerides.
The diagnosis is mainly supported by the presence of markedly elevated TG concentrations and CM, the latter of which is normally rapidly cleared from the plasma following a meal. The current treatment involves the restriction of the dietary fat intake allied with traditional TG-lowering agents like fibrates, statins, and niacin's. However, there is no US Food and Drug Administration (FDA) approved drug for the treatment of FCS, but in May 2019, Waylivra (volanesorsen) was conditionally approved by the European Commission (EC) for the treatment of FCS.
Familial Chylomicronemia Syndrome Market Key Facts
-
Among the 7MM, Germany captured the highest Familial Chylomicronemia Syndrome market in 2022, with an estimated USD 5 million in 2022, which is anticipated to grow during the forecast period.
-
In 2022, EU4 and the UK captured nearly 90% of the total market in the 7MM, whereas Japan had the lowest market.
-
Among the forecasted emerging therapies, Olezarsen (ApoC-III) is expected to capture the highest market in the 7MM by 2032.
-
The total Familial Chylomicronemia Syndrome diagnosed with prevalent cases in the 7MM is expected to rise by 2032. However, the rise in many cases is not significant as FCS is an ultra-rare indication and is underdiagnosed.
-
The United States showed the highest Familial Chylomicronemia Syndrome diagnosed prevalent population compared to other 7MM countries, with 1.3K cases in 2022. As per DelveInsight’s estimates, the country alone accounts for nearly 65% of Familial Chylomicronemia Syndrome diagnosed prevalent cases in the 7MM countries.
-
EU4 and the UK countries accounted for nearly 485 Familial Chylomicronemia Syndrome diagnosed prevalent cases in 2022. Of these cases, 135 cases were estimated in Germany, accounting for the highest number of Familial Chylomicronemia Syndrome diagnosed prevalent cases in Europe.
-
Japan accounted for 12% of the total Familial Chylomicronemia Syndrome diagnosed prevalent cases in the 7MM in 2022.
Familial Chylomicronemia Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Familial Chylomicronemia Syndrome pipeline therapies. It also thoroughly assesses the Familial Chylomicronemia Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Familial Chylomicronemia Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Familial Chylomicronemia Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Familial Chylomicronemia Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Familial Chylomicronemia Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Familial Chylomicronemia Syndrome Epidemiology, Segmented as -
-
Diagnosed prevalent cases of Familial Chylomicronemia Syndrome in the 7MM
-
Age-specific diagnosed prevalent cases of Familial Chylomicronemia Syndrome in the 7MM
Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to be launched during the study period. The analysis covers the Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Familial Chylomicronemia Syndrome drugs based on their sale and market share.
The report also covers the Familial Chylomicronemia Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Familial Chylomicronemia Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Familial Chylomicronemia Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market
Familial Chylomicronemia Syndrome Therapeutics Analysis
Current treatment choices for FCS can be fragmented into managing acute crises related to pancreatitis and chronic management of hypertriglyceridemia to reduce the risk of future episodes. During an episode of acute pancreatitis, complete fasting with parenteral fluid support and analgesia if required is usually very effective.
The present mainstay therapy for FCS is a very-low-fat diet (less than 20 g per day) allied with traditional trigelyceride-lowering medication. However, it is noteworthy to mention that such types of diets are very difficult for patients to follow. So, for this type of standard of care to be effective, long‐term patient education, and support aligned mainly to maintain a low‐fat diet is required. In everyday life, adherence to such a regimen is very challenging and is almost never consistently achieved by most patients.
Several major pharma and biotech companies are developing therapies for Familial Chylomicronemia Syndrome. Currently, Ionis Pharmaceuticals is leading the therapeutics market with its Familial Chylomicronemia Syndrome drug candidates in the most advanced stage of clinical development.
Familial Chylomicronemia Syndrome Companies Actively Working in the Therapeutics Market Include
-
Akcea Therapeutics
-
Arrowhead Pharmaceuticals
-
Ionis Pharmaceuticals
-
Lipigon Pharmaceuticals
-
Novartis Pharmaceuticals
-
Pfizer
-
UniQure Biopharma B.V.
And Many Others
Emerging and Marketed Familial Chylomicronemia Syndrome Therapies Covered in the Report Include:
-
Olezarsen: Ionis Pharmaceuticals
-
WAYLIVRA (volanesorsen): Akcea Therapeutics Ireland Limited
-
ARO-APOC3: Arrowhead Pharmaceuticals, Inc
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Familial Chylomicronemia Syndrome Competitive Intelligence Analysis
4. Familial Chylomicronemia Syndrome Market Overview at a Glance
5. Familial Chylomicronemia Syndrome Disease Background and Overview
6. Familial Chylomicronemia Syndrome Patient Journey
7. Familial Chylomicronemia Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Familial Chylomicronemia Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Familial Chylomicronemia Syndrome Unmet Needs
10. Key Endpoints of Familial Chylomicronemia Syndrome Treatment
11. Familial Chylomicronemia Syndrome Marketed Therapies
12. Familial Chylomicronemia Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Familial Chylomicronemia Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Familial Chylomicronemia Syndrome Market Outlook (In US, EU5, and Japan)
16. Familial Chylomicronemia Syndrome Companies Active in the Market
17. Familial Chylomicronemia Syndrome Access and Reimbursement Overview
18. KOL Views on the Familial Chylomicronemia Syndrome Market
19. Familial Chylomicronemia Syndrome Market Drivers
20. Familial Chylomicronemia Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
"Periodontal Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Periodontal Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Periodontal Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
